IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
VISN News
Archived Headlines
- US IPO Week Ahead: May set to kick off with a 10 IPO week 04/30/21
- US IPO Weekly Recap: Coinbase’s direct listing headlines a 9 IPO week 04/16/21
- UK-based biotech Gyroscope Therapeutics Holdings files for a $100 million US IPO 04/16/21
- Top weekly performers: VisionChina Media, OSG America L.P., Rackspace 09/26/09
- ALERT: Worst weekly perfomers: VisionChina Media, comScore, Sucampo Pharmaceuticals 05/02/09
See more
UK-based biotech Gyroscope Therapeutics withdraws $142 million US IPO
Gyroscope Therapeutics Holdings, a UK-based Phase 2 biotech developing gene therapies for ocular diseases, withdrew its plans for an initial public offering on Thursday. It had filed to raise $142 million in May by offering 6.8 million ADSs at a price range of $20 to $22, but postponed ahead of pricing. The Hertfordshire, United Kingdom-based company was founded in 2016 and...read more
US IPO Weekly Recap: Sacramento bank Five Star Bancorp finishes on top in an 8 IPO week
Eight IPOs and four SPACs went public this past week. One IPO postponed, UK-based biotech Gyroscope Therapeutics (VISN), citing market conditions. Filing activity maintained a comfortable pace/remained moderate, with seven IPOs and 10 SPACs submitting initial filings. The week’s best performer, Sacramento bank Five Star Bancorp (FSBC)...read more
UK-based biotech Gyroscope Therapeutics postpones $142 million US IPO
Gyroscope Therapeutics Holdings, a UK-based Phase 2 biotech developing gene therapies for ocular diseases, postponed its IPO on Friday, citing market conditions. It had filed to raise $142 million by offering 6.8 million ADSs at a price range of $20 to $22. The Hertfordshire, United Kingdom-based company was founded in 2016 and booked $1 million in sales for the 12 months ended...read more
UK-based biotech Gyroscope Therapeutics sets terms for $142 million US IPO
Gyroscope Therapeutics Holdings, a UK-based Phase 2 biotech developing gene therapies for ocular diseases, announced terms for its IPO on Monday. The Hertfordshire, United Kingdom-based company plans to raise $142 million by offering 6.8 million ADSs at a price range of $20 to $22. At the midpoint of the proposed range, Gyroscope Therapeutics Holdings would command a fully...read more